Dossier structure and content for pandemic-influenza-vaccine marketing-authorisation application - Scientific guideline

This document provides the basis for a fast track authorisation procedure for pandemic influenza vaccines within the European Union. It assists with the documentation to be included in the core pandemic dossier and pandemic variation application for inactivated influenza vaccines.

The quality requirements of this guideline have been replaced by the guideline on influenza vaccines - quality module.

Keywords: Pandemic influenza vaccine for human use, core pandemic dossier, mock-up vaccine, quality requirements, non-clinical requirements, clinical requirements

Current version

Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded

Adopted Reference Number: EMEA/CPMP/VEG/4717/2003- Rev.1 Legal effective date: 01/01/2009

Draft guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision) - Superseded

Draft: consultation closed Reference Number: EMEA/CPMP/VEG/4717/03- Rev.1

Concept paper on the revision of the guideline on dossier structure and content for pandemic influenza marketing authorisation application (CPMP/VEG/4717/03) - Superseded

Reference Number: EMEA/CHMP/166042/2007